Sentiment Trading

Genmab A/S is preparing to showcase its epcoritamab development program at the 2025 European Hematology Association Congress, amidst market fluctuations and a share buy-back program aimed at optimizing its capital structure.

Genmab A-S continues to make strategic moves to drive growth and enhance shareholder value, positioning itself as a leader in the global health care industry.